Tercica Increlex Hypoglycemia Risk Mitigated By Dose Timing, Titration - FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth therapy merited labeling precaution but not rejection of NDA, as sought by competitor Insmed in citizen petition, FDA review documents state.